[[{"@type":["BlogPosting"],"@id":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/#BlogPosting","@context":{"@vocab":"http:\/\/schema.org\/","kg":"http:\/\/g.co\/kg"},"url":["https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/","https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/"],"publisher":[{"@id":"https:\/\/www.regionalcancercare.org\/"}],"author":[{"@type":"Organization","@id":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/#BlogPosting_author_Organization","name":"Regional Cancer Care Associates"}],"inLanguage":"en-US","image":[{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/#BlogPosting_image_ImageObject","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Doctor-And-Patient-Talking.jpg"}],"headline":"Cancers Most Likely To Benefit From Targeted Monoclonal Immunotherapy","dateModified":"2021-11-11T12:03:14+00:00","datePublished":"2020-04-21T05:38:35+00:00","description":"Targeted monoclonal immunotherapy for cancer is now used for more than ten different types of the disease. Do you know which ones? Visit the Regional Cancer Care Associates blog to learn more about this progressive treatment option.","articleBody":"\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\tApril 21, 2020\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\nOne of the most effective ways to treat cancer is to harness the power of the body\u2019s own immune system. This method is called immunotherapy. While immunotherapy comes in many different forms, one type that\u2019s gaining traction is called targeted monoclonal immunotherapy for cancer. Monoclonal antibodies are being used to treat patients of Regional Cancer Care Associates right now, as it\u2019s been approved for several different types of cancer.\nHow Monoclonal Antibodies Work\nAntibodies are a natural part of the body\u2019s immune system. Their job is to bind themselves to an antigen on abnormal cells, signaling to the immune system that these cells need to be destroyed. Once researchers figure out which antigen on a cancer cell needs to be attacked, they can then develop a monoclonal antibody. Monoclonal antibodies are produced in a laboratory and then administered through a patient\u2019s vein. Think of them as substitute antibodies to help the immune system fight back against cancer.\nMonoclonal antibodies can function in different ways depending on what the type of cancer necessitates. They can be used to accomplish the following:\nFlag cancerous cells for attackTrigger cell-membrane destructionBlock cell growthPrevent blood vessel growthAttack cancer cells directlyTrigger immune system checkpoints\nOne example of a monoclonal antibody is called alemtuzumab (Campath), which treats chronic lymphocytic leukemia (CLL). The antibody works by binding to the CD52 antigen on lymphocytes. This binding then attracts the body\u2019s immune cells to come and destroy those cancerous lymphocytes.\nCancers That Benefit the Most from Monoclonal Antibodies\nBecause monoclonal antibodies are so versatile, they can fight several cancers. If you have any of the following types of cancer, this treatment may be an option that\u2019s available to you:\nBrain cancerBreast cancerLeukemiaColorectal cancerHead and neck cancersHodgkin\u2019s and non-Hodgkin\u2019s lymphomaLung cancerMelanomaProstate cancerStomach cancer\nMonoclonal antibodies are still being developed for other types of cancers, as well, which some patients may have access to via clinical trials at RCCA.\nSide Effects of Monoclonal Antibodies\nLike most cancer treatments, monoclonal antibodies can cause some side effects. Every patient reacts differently to the treatment, but side effects are typically mild. The most common side effect is a skin reaction at the needle site, such as pain, swelling, redness, and itchiness. Flu-like symptoms are also common, such as chills, fever, and fatigue. Additional side effects may include:\nMuscle aches and painsNauseaVomitingDiarrheaMouth and skin soresChanges in blood pressure\nRegional Cancer Care Associates is dedicated to providing the highest level of care possible. That\u2019s why patients can count on RCCA for the latest and most effective treatment options at all of our Connecticut, Maryland, and New Jersey locations. If you\u2019re interested in learning more about targeted monoclonal immunotherapy for cancer, be sure to speak to one of our cancer specialists. And if monoclonal antibodies aren\u2019t right for you, rest assured that many other treatment options are available, from chemotherapy and radiation to surgery and cryotherapy. Contact us today to set up an appointment.\nwe are here for you\nFor more information or to schedule an appointment, call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.\nRELATED ARTICLES\nRegional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.\n\u00a9 2022 Regional Cancer Care Associates. All rights reserved.","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/"},{"@context":"http:\/\/schema.org","@type":"LocalBusiness","address":{"@type":"PostalAddress","streetAddress":"Corporate Office 25 Main Street, Suite 601","postalCode":"07601","addressRegion":"NJ","addressLocality":"Hackensack","addressCountry":"USA","name":"Postal Address","@id":"https:\/\/www.regionalcancercare.org\/#PostalAddress"},"logo":{"@type":"ImageObject","width":"1024","height":"468","url":"https:\/\/www.regionalcancercare.org\/wp-content\/themes\/rccah\/dist\/images\/RCCA_logo.jpg","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/themes\/rccah\/dist\/images\/RCCA_logo.jpg"},"image":{"@id":"https:\/\/www.regionalcancercare.org\/wp-content\/themes\/rccah\/dist\/images\/RCCA_logo.jpg"},"contactPoint":[{"@type":"ContactPoint","contactOption":"https:\/\/www.regionalcancercare.org\/contact\/#ContactPointOption","availableLanguage":"https:\/\/en.wikipedia.org\/wiki\/English_language","areaServed":["https:\/\/en.wikipedia.org\/wiki\/New_Jersey","https:\/\/en.wikipedia.org\/wiki\/Hackensack,_New_Jersey"],"contactType":"customer support","telephone":"+1 (844) 346-7222","email":"info@regionalcancercare.org","description":"Corporate Office Regional Cancer Care Associates 25 Main Street, Suite 601 Hackensack, NJ 07601 info@regionalcancercare.org Phone: (844) 346-7222","name":"Contact Corporate Office","image":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2017\/06\/RCCA_logo-300x137.jpg","url":"https:\/\/www.regionalcancercare.org\/contact\/","@id":"https:\/\/www.regionalcancercare.org\/contact\/#CorporateOffice"},{"@type":"ContactPoint","contactOption":"https:\/\/www.regionalcancercare.org\/contact\/#ContactPointOption","availableLanguage":"https:\/\/en.wikipedia.org\/wiki\/English_language","areaServed":["https:\/\/en.wikipedia.org\/wiki\/New_Jersey","https:\/\/en.wikipedia.org\/wiki\/Hackensack,_New_Jersey"],"contactType":"customer support","telephone":"+1 (201) 510-0922","email":"msalvemini@regionalcancercare.org","description":"Media Inquiries: Mary Lou Salvemini Regional Cancer Care Associates Phone: (201) 510-0922 Email: msalvemini@regionalcancercare.org","name":"Contact Media Inquiries","image":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2017\/06\/RCCA_logo-300x137.jpg","url":"https:\/\/www.regionalcancercare.org\/contact\/","@id":"https:\/\/www.regionalcancercare.org\/contact\/#MediaInquiries"}],"areaServed":["https:\/\/en.wikipedia.org\/wiki\/Hackensack,_New_Jersey","https:\/\/en.wikipedia.org\/wiki\/New_Jersey"],"additionalType":"https:\/\/en.wikipedia.org\/wiki\/Treatment_of_cancer","alternateName":"RCCA","description":"Leaders in Advanced Compassionate Cancer Care. Fight cancer with leading-edge treatments, experienced skill and local caring\/convenience from one of the nation's largest networks of cancer specialists.","email":"info@regionalcancercare.org","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/","url":"https:\/\/www.regionalcancercare.org\/","sameAs":["https:\/\/twitter.com\/rgnlcancercare","https:\/\/www.facebook.com\/regionalcancercareassoc","https:\/\/www.linkedin.com\/company\/10059183","https:\/\/www.youtube.com\/channel\/UCFlVzU4UvZcyXBCe9ZSvAUQ"],"telephone":"+1 (844) 346-7222","name":"Regional Cancer Care Associates","@id":"https:\/\/www.regionalcancercare.org\/"}],{"@context":"https:\/\/schema.org\/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/www.regionalcancercare.org\/news\/#breadcrumbitem"},{"@type":"ListItem","position":2,"name":"Cancers Most Likely To Benefit From Targeted Monoclonal Immunotherapy","item":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/#breadcrumbitem"}]}]